Independent hormone therapy for precancer and initial endometrial cancer: pros and cons
Vol. 60 No. 3 (2014), Articles
Vol. 60 No. 3 (2014)

Independent hormone therapy for precancer and initial endometrial cancer: pros and cons

Articles
https://doi.org/10.37469/0507-3758-2014-60-3-306-312
Published 15.12.2014
P.A. Herzen Moscow Research Oncology Institute
Russian Medical Academy of Postgraduate Education
P.A. Herzen Moscow Research Oncology Institute
P.A. Herzen Moscow Research Oncology Institute
P.A. Herzen Moscow Research Oncology Institute
P.A. Herzen Moscow Research Oncology Institute
Russian Medical Academy of Postgraduate Education
P.A. Herzen Moscow Research Oncology Institute
P.A. Herzen Moscow Research Oncology Institute
##article.numberofdownloads## 143
##article.numberofviews## 223
PDF (Русский)

Keywords

endometrial atypical hyperplasia
endometrial cancer
hormone therapy
preservation of fertility

How to Cite

, , , , , , , , & . (2014). Independent hormone therapy for precancer and initial endometrial cancer: pros and cons. Voprosy Onkologii, 60(3), 306–312. https://doi.org/10.37469/0507-3758-2014-60-3-306-312
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

There are presented the results of conservative treatment of 121 patients with endometrial atypical hyperplasia (EAH) and the initial endometrial cancer (EC) with preservation of fertility. In EAH (n = 56) during 6 months there was used the intrauterine spiral Mirena. The efficiency was 91 %, the recurrence rate - 16 %, pregnancies occurred in 16 % of patients. In EC (n = 65) hormone therapy was conducted during 6 months using the intrauterine spiral Mirena and zoladex. The efficiency was 79 %, recurrence rate - 22 %, pregnancies occurred in 24 % of patients. Basing on own data and the results of other studies the benefits and risks of independent hormone therapy for EAH and EC are discussed in women of reproductive age.
https://doi.org/10.37469/0507-3758-2014-60-3-306-312
##article.numberofdownloads## 143
##article.numberofviews## 223
PDF (Русский)

References

Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 г. (заболеваемость и смертность) // М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. - 2014. - 258 C.

Максимов С.Я. Минимальный рак эндометрия // Практ. онкол. - 2004. - Т. 5. - № 1. - C. 60-67.

Новикова Е.Г., Чулкова О.В., Пронин С.М. Предрак и начальный рак эндометрия у женщин репродуктивного возраста // МИА. - Москва. - 2005. - 132 C.

Пашов А.И., Цхай В.Б., Сивова Е.Н. Комплексная гормонотерапия агонистами ГнРГ и внутриматочной левоноргестрел-рилизинг системой сложной атипической гиперплазии и аденокарциномы эндометрия: пилотное проспективное наблюдательное исследование // Злокачественные опухоли. - 2012. - T. 2. - № 1. - C. 15-17.

Рубцова Н.А., Новикова Е.Г., Синицын В.Е. и др. Рак эндометрия: предоперационное стадирование. Сопоставление информативности ультразвукового исследования и магнитно-резонансной томографии // Вестн. рентгенрадиол. радиол. - 2012. - № 4. - С. 33-44.

Урманчеева А.Ф., Ульрих Е.А., Михайлюк Г.И. Современная гормонотерапия рака эндометрия // Сиб. Онкол. журнал. - 2007. - Приложение. - C. 89-93.

Berek J.S., Hacker N.F. Practical Gynecologic Oncology // - Lipincott Williams & Wilkins. - 2000. - 937 P.

Bokhman J.V., Chepick O.F., Volkova A.T., Vishnevsky A.S. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? // Gynecol Oncol. - 1985. - Vol. 20. - P. 139-155.

Dhar K.K., NeedhiRajan T., Koslowski M., Woolas R.P. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature // Gynecol Oncol. - 2005. - Vol. 97. - P. 924.

DiSaia P.J., Creasman W.T. Clinical Gynecologic Oncology // 7th edition. - Mosby Elsevier. - 2007. - 812 P.

Gallos I.D., Yap J., Rajkhowa M. et al. Regression, relapse and live birth rates after fertility sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: systematic review and metanalysis // Am J. Obstet. Gynecol. - 2012. - Vol. 207. - P. 1-12.

Gotlieb W.H., Beiner M.E., Shalmon B. et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer // Obstet Gynecol. - 2003. - Vol. 102. - P. 718.

Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review // Gynecol Oncol. - 2012. - Vol. 125. - P. 477.

Ichinose M., Fujimoto A., Osuga Y. et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia // Int. J. Gynecol. Cancer. - 2013. - Vol. 23. - P. 288-293.

Jadoul P., Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma // Fertil Steril. - 2003. - Vol. 80. - P. 1315.

Kinkel K., Kaji Y., Yu K.K. et al. Radiologic staging in patients with endometrial cancer: a meta-analysis // Radiology. - 1999. - Vol. 212. - P. 711.

Mazzon I., Corrado G., Masciullo V. et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation // Fertil Steril. - 2010. - Vol. 93. - P. 1286.

Montz F.J., Bristow R.E., Bovicelli A. et al. Intrauterine progesterone treatment of early endometrial cancer // Am. J. Obstet. Gynecol. - 2002. - Vol. 186. - P. 651.

Perry T., Korach J., Goetlieb W.H. et al. Prolonged con-cervative treatment of endometrial cancer patients. More than one pregnancy can be achieved // Int. J. Gynecol. Cancer. - 2011. - Vol. 21. - Р. 72-78.

Walsh C., Holschneider C., Hoang Y., et al. Coexisting ovarian malignancy in young women with endometrial cancer // Obstet Gynecol. - 2005. - Vol. 106. - P. 693-699.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...